Skip to main content
    B

    BioRestorative Therapies Inc (BRTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.42
    -0.07 (-4.70%)

    Market Cap: $2.06M

    Last updated: Nov 17, 2026 at 11:00 AM ET

    BioRestorative Therapies Inc (BRTX) Earnings: Report Dates and Results

    Updated Nov 11, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    BioRestorative Therapies (BRTX) is expected to report earnings on Mar 24, 2027. In the quarter ended Sep 30, 2026, BioRestorative Therapies reported EPS of -$7.60, below the -$2.60 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    65%(13/20)
    Avg Surprise
    -4.81%

    Upcoming Estimates

    Reports Mar 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$2.04
    Range-$2.55 - -$1.47
    4 analysts
    Revenue Consensus
    $395.25K
    Range$98.00K - $708.75K
    4 analysts

    Next Report

    BRTX has an expected report date of Mar 24, 2027.

    BRTX Earnings Call

    The latest BRTX earnings call transcript on file is labeled 2025Q3.

    Read the 2025Q3 transcript

    Earnings History

    Of the 20 quarters below that had an estimate, BRTX beat 13, missed 6 and matched 1. The widest gap in the table came in the quarter ended Sep 30, 2026, when EPS landed 192.31% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$7.60-$2.60-$2.60 - -$2.60-192.31%MissN/A11 up, 0 downNov 11, 2026N/A
    Jun 30, 2026$6.00$3.00N/A+100.00%BeatN/A11 up, 0 downAug 31, 2026N/A
    Mar 31, 2026-$0.12-$0.30-$0.30 - -$0.30+60.00%BeatN/A11 up, 0 downMay 14, 2026$23170
    Dec 31, 2025-$0.32-$0.34N/A+5.88%BeatN/A10 up, 1 downMar 26, 2026$19600
    Sep 30, 2025-$0.33-$0.38-$0.38 - -$0.38+13.16%BeatN/A10 up, 1 downNov 12, 2025$11800
    Jun 30, 2025-$0.30-$0.41-$0.41 - -$0.41+26.83%BeatN/A10 up, 1 downAug 12, 2025$303300
    Mar 31, 2025-$0.64-$0.32-$0.32 - -$0.32-100.00%MissN/A10 up, 1 downMay 14, 2025$25000
    Dec 31, 2024-$0.38-$0.55N/A+32.22%BeatN/A10 up, 1 downMar 27, 2025$43300
    Sep 30, 2024-$0.01-$0.35-$0.51 - -$0.35+97.14%BeatN/A21 up, 0 downNov 12, 2024$233600
    Jun 30, 2024-$0.28-$0.56-$0.56 - -$0.56+50.00%BeatN/A10 up, 0 downAug 13, 2024$89100
    Mar 31, 2024-$0.59-$0.51-$0.53 - -$0.51-15.69%MissN/A20 up, 0 downJun 11, 2024$35000
    Dec 31, 2023-$0.57-$0.69-$0.73 - -$0.65+17.39%BeatN/A20 up, 0 downMar 29, 2024$19300
    Sep 30, 2023-$0.64-$0.68-$0.68 - -$0.68+5.88%BeatN/A10 up, 0 downNov 13, 2023$30700
    Jun 30, 2023-$0.77-$1.56-$1.56 - -$0.82+50.64%BeatN/A20 up, 0 downAug 11, 2023$64500
    Mar 31, 2023-$1.53-$1.26-$1.26 - -$1.26-21.43%MissN/A11 up, 0 downMay 12, 2023$31300
    Dec 31, 2022-$1.18-$1.35-$1.56 - -$1.30+12.59%BeatN/A20 up, 0 downMar 24, 2023$3700
    Sep 30, 2022-$1.28-$1.45-$1.45 - -$1.45+11.72%BeatN/A10 up, 0 downNov 14, 2022$29000
    Jun 30, 2022-$1.28-$0.55-$0.55 - -$0.55-132.73%MissN/A10 up, 0 downAug 15, 2022$71100
    Mar 31, 2022-$1.37-$0.63-$0.63 - -$0.63-117.46%MissN/A10 up, 0 downMay 16, 2022$16000
    Dec 31, 2021-$6.90-$0.54-$0.54 - -$0.54N/AN/AN/A10 up, 0 downMar 30, 2022$5000
    Sep 30, 2021-$4.99-$4.99N/A0.00%In lineN/AN/AN/ANov 15, 2021$8000
    Jun 30, 2021-$5.10N/AN/AN/AN/A-103.5%N/AN/AAug 16, 2021$15000
    Mar 31, 2021-$0.01N/AN/AN/AN/AN/AN/AN/AMay 17, 2021$18000
    Dec 31, 2020-$0.04N/AN/AN/AN/AN/AN/AN/AMar 29, 2021$17000
    Sep 30, 2020-$41.95N/AN/AN/AN/AN/AN/AN/ASep 30, 2020$15000
    Jun 30, 2020$144.27N/AN/AN/AN/AN/AN/AN/AJun 30, 2020$19000
    Mar 31, 2020-$629.18N/AN/AN/AN/AN/AN/AN/AJun 29, 2020$26000
    Dec 31, 2019-$0.01N/AN/AN/AN/AN/AN/AN/AMar 30, 2020$32000
    Sep 30, 2019-$0.23N/AN/AN/AN/AN/AN/AN/ANov 13, 2019$38000
    Jun 30, 2019-$0.24N/AN/AN/AN/AN/AN/AN/AAug 14, 2019$31000
    Mar 31, 2019-$0.28N/AN/AN/AN/AN/AN/AN/AMay 14, 2019$29000
    Dec 31, 2018-$0.35N/AN/AN/AN/AN/AN/AN/AMar 29, 2019$29000
    Sep 30, 2018-$0.39N/AN/AN/AN/AN/AN/AN/ANov 13, 2018$26000
    Jun 30, 2018-$0.53N/AN/AN/AN/AN/AN/AN/AAug 14, 2018$37000
    Mar 31, 2018-$0.33N/AN/AN/AN/AN/AN/AN/AApr 2, 2018$19000
    Dec 31, 2017-$0.39N/AN/AN/AN/AN/AN/AN/AMar 31, 2018$38000
    Sep 30, 2017-$0.37N/AN/AN/AN/AN/AN/AN/ANov 14, 2017$16000
    Jun 30, 2017-$0.37N/AN/AN/AN/AN/AN/AN/AAug 14, 2017$20000
    Mar 31, 2017-$0.51N/AN/AN/AN/AN/AN/AN/AMay 15, 2017$7000
    Dec 31, 2016-$0.56N/AN/AN/AN/AN/AN/AN/AMar 21, 2017$6075
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.59, after -$1.26 the year before. It was -$2.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.59N/A
    Dec 31, 2024-$1.26N/A
    Dec 31, 2023-$3.51N/A
    Dec 31, 2022-$5.11N/A
    Dec 31, 2021-$17.00N/A
    Dec 31, 2020-$526.91N/A
    Dec 31, 2019-$0.76N/A
    Dec 31, 2018-$1.60N/A
    Dec 31, 2017-$1.64N/A
    Dec 31, 2016-$2.00N/A

    Earnings Calls

    The 5 most recent earnings calls are listed below; the latest, 2025Q3 for the period ended Sep 30, 2025, runs about 4,100 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2025Q3Sep 30, 20254,1467
    2025Q2Jun 30, 20252,8697
    2025Q1Mar 31, 20253,2657
    2024Q3Sep 30, 20243,9737
    2024Q2Jun 30, 20244,3639

    2025Q3 Earnings Call

    Opening remarks

    Stephen Kilmer Investor Relations Thank you. Good afternoon, everyone. Let me start by pointing out that this conference call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are based on BioRestorative Therapies' current beliefs, assumptions, and expectations. Such statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. No forward-looking statement can be guaranteed. For details on factors, among others, that could affect expectations, see Part 1, Item 1A of our annual report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission. Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this conference call. BioRestorative Therapies undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law. On the call today, representing the company are Lance Alstodt, BioRestorative Therapies' President, Chairman, and Chief Executive Officer; Francisco J. Silva, Vice President of Research and Development; and Robert Eugene Kristal, the company's Chief Financial Officer. With that said, I'll now turn the call over to Lance.

    Lance Alstodt CEO Thanks, Stephen, and good afternoon, everyone. Welcome. On behalf of the management team and everyone at BioRestorative Therapies, I would like to thank you for your interest in our company. For those of you who are shareholders, we appreciate your continued support. As you can see from the press release we issued just a short time ago, we continue to execute well across all areas of our business in the third quarter. We have a lot of exciting things to look forward to as we move through the last couple of months of the year. With that said, I'd like to ask Robert Eugene Kristal, our CFO, to provide a brief overview of our third-quarter financial results.

    Robert Eugene Kristal CFO Thanks, Lance. Good afternoon, everyone. To streamline the presentation of the financial results, all the numbers I will refer to have been rounded, so they are approximate. Third-quarter 2025 revenues were $11,800 and consisted entirely of royalty revenue. This compares to revenues of $233,600 in Q3 2024, the vast majority of which came from biocosmeceutical sales in connection with our exclusive supply agreement with Cartessa. The overall year-over-year decrease in Q3 2025 revenues was driven by the timing of orders for the developing biocosmeceutical revenue stream. The company's third-quarter 2025 loss from operations was $3.7 million compared to $2.3 million for the comparable period of 2024.

    Frequently Asked Questions About BRTX

    When is BioRestorative Therapies's next earnings date?

    BioRestorative Therapies's next earnings report is expected for Mar 24, 2027.

    Did BRTX beat earnings estimates last quarter?

    No. BioRestorative Therapies reported EPS of -$7.60 for the quarter ended Sep 30, 2026, below the -$2.60 estimate by 192.31%.

    What EPS do analysts expect from BRTX next quarter?

    The consensus EPS estimate for BioRestorative Therapies for the quarter ending Dec 31, 2026 is -$2.04 from 4 analysts, with estimates from -$2.55 to -$1.47.

    How often does BRTX beat earnings estimates?

    BioRestorative Therapies beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of -6.78%.